ABSORB China: Two-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Runlin Gao

REGISTER for free or LOG IN to view this content

ABSORB China: Two-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Up Next

More slides +

We Recommend